MX368346B - Derivados de 1,6- diazabiciclo [3.2,1] octano-7-ona y su uso en el tratamiento de las infecciones bacterianas. - Google Patents

Derivados de 1,6- diazabiciclo [3.2,1] octano-7-ona y su uso en el tratamiento de las infecciones bacterianas.

Info

Publication number
MX368346B
MX368346B MX2015002177A MX2015002177A MX368346B MX 368346 B MX368346 B MX 368346B MX 2015002177 A MX2015002177 A MX 2015002177A MX 2015002177 A MX2015002177 A MX 2015002177A MX 368346 B MX368346 B MX 368346B
Authority
MX
Mexico
Prior art keywords
bacterial infections
octan
diazabicyclo
derivatives
treatment
Prior art date
Application number
MX2015002177A
Other languages
English (en)
Other versions
MX2015002177A (es
Inventor
Vithalbhai Patel Mahesh
Bhagwat Sachin
Jagdishwar Patil Vijaykumar
Tadiparthi Ravikumar
Dond Bharat
Usman Shaikh Mohammad
Dekhane Deepak
Ambalal Patel Piyush
Kale Amol
Velupillai Loganathan
Shrimant Birajdar Satish
Maurya Sushilkumar
Dixit Prasad
Pawar Mangesh
Original Assignee
Wockhardt Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wockhardt Ltd filed Critical Wockhardt Ltd
Publication of MX2015002177A publication Critical patent/MX2015002177A/es
Publication of MX368346B publication Critical patent/MX368346B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/62—Quaternary ammonium compounds
    • C07C211/63—Quaternary ammonium compounds having quaternised nitrogen atoms bound to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Los compuestos de Fórmula (I), su preparación y uso en la prevención o tratamiento de infecciones bacterianas se dan a conocer. (ver Fórmula).
MX2015002177A 2012-08-25 2013-04-19 Derivados de 1,6- diazabiciclo [3.2,1] octano-7-ona y su uso en el tratamiento de las infecciones bacterianas. MX368346B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN2471MU2012 2012-08-25
PCT/IB2013/053092 WO2014033560A1 (en) 2012-08-25 2013-04-19 1,6- diazabicyclo [3,2,1] octan- 7- one derivatives and their use in the treatment of bacterial infections

Publications (2)

Publication Number Publication Date
MX2015002177A MX2015002177A (es) 2015-04-10
MX368346B true MX368346B (es) 2019-09-27

Family

ID=54187095

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015002177A MX368346B (es) 2012-08-25 2013-04-19 Derivados de 1,6- diazabiciclo [3.2,1] octano-7-ona y su uso en el tratamiento de las infecciones bacterianas.

Country Status (14)

Country Link
US (5) US20150203503A1 (es)
EP (2) EP3360877B1 (es)
JP (2) JP6329147B2 (es)
KR (1) KR101946107B1 (es)
CN (1) CN104768951B (es)
AU (2) AU2013308127B2 (es)
BR (1) BR112015003592B1 (es)
CA (1) CA2881169C (es)
ES (1) ES2672100T3 (es)
MX (1) MX368346B (es)
NZ (1) NZ626314A (es)
RU (1) RU2614418C2 (es)
WO (1) WO2014033560A1 (es)
ZA (1) ZA201500970B (es)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9505761B2 (en) 2011-12-02 2016-11-29 Fedora Pharmaceuticals Inc. Bicyclic compounds and their use as antibacterial agents and beta-lactamase inhibitors
US8796257B2 (en) 2011-12-02 2014-08-05 Naeja Pharmaceutical Inc. Bicyclic compounds and their use as antibacterial agents and β-lactamase inhibitors
AR090539A1 (es) 2012-04-02 2014-11-19 Astrazeneca Ab COMPUESTOS INHIBIDORES DE b LACTAMASA
WO2013180197A1 (ja) * 2012-05-30 2013-12-05 Ｍｅｉｊｉ Ｓｅｉｋａファルマ株式会社 新規β－ラクタマーゼ阻害剤とその製造法
WO2014033560A1 (en) * 2012-08-25 2014-03-06 Wockhardt Limited 1,6- diazabicyclo [3,2,1] octan- 7- one derivatives and their use in the treatment of bacterial infections
UA111925C2 (uk) * 2012-12-11 2016-06-24 Федора Фармасьютікалз Інк. БІЦИКЛІЧНІ СПОЛУКИ ТА ЇХ ВИКОРИСТАННЯ ЯК АНТИБАКТЕРІАЛЬНИХ АГЕНТІВ ТА ІНГІБІТОРІВ β-ЛАКТАМАЗИ
CN105612159A (zh) * 2013-10-08 2016-05-25 明治制果药业株式会社 二氮杂二环辛烷衍生物的结晶及其制备方法
IN2013MU03421A (es) * 2013-10-30 2015-07-17 Wockhardt Ltd
US9604986B2 (en) 2013-11-26 2017-03-28 Wockhardt Limited Polymorphs and process for preparation of (2S, 5R)-7-oxo-N-[(2S)-pyrrolidin-2-yl-methyloxy]-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
KR20160090311A (ko) * 2013-11-26 2016-07-29 욱크하르트 리미티드 항균성 조성물
WO2015110886A1 (en) * 2014-01-21 2015-07-30 Wockhardt Limited A process for preparation of (2s, 5r)-7-oxo-n-[(3s)-pyrrolidin-3-yloxy]-6-(sulfooxy)-1,6-diazabicyclo [3.2.1]octane-2-carboxamide
WO2015148379A1 (en) 2014-03-24 2015-10-01 Novartis Ag Monobactam organic compounds for the treatment of bacterial infections
BR112016022439A2 (pt) * 2014-03-29 2017-08-15 Wockhardt Ltd Composições farmacêuticas que compreendem cefepima ou sulbactama
DK3221313T3 (en) 2014-11-17 2019-04-08 Entasis Therapeutics Ltd COMBINATION THERAPY FOR TREATING INFECTIONS WITH RESISTANT BACTERIA
WO2016128867A1 (en) * 2015-02-12 2016-08-18 Wockhardt Limited Azetidinone containing compounds and their use in treatment of bacterial infections
EP3075734A1 (en) * 2015-03-31 2016-10-05 Mutabilis Heterocyclic compounds and their use in preventing or treating bacterial infections
CA2980109A1 (en) * 2015-03-31 2016-10-06 Mutabilis Heterocyclic compounds and their use in preventing or treating bacterial infections
WO2017002086A1 (en) * 2015-07-02 2017-01-05 Wockhardt Limited Nitrogen containing bicyclic compounds and their use in treatment of bacterial infections
WO2017002089A1 (en) * 2015-07-02 2017-01-05 Wockhardt Limited Nitrogen containing bicyclic compounds and their use in treatment of bacterial infections
WO2017060826A1 (en) * 2015-10-06 2017-04-13 Wockhardt Limited Difluoro-(2-substituted carbamoyl-1,6-diaza-bicyclo [3.2.1] oct-6-yloxy) acetic acid compounds and their use in treatment of bacterial infections
WO2017081615A1 (en) * 2015-11-09 2017-05-18 Wockhardt Limited 7-oxo -6-(sulfooxy)- 1,6-diazabicyclo [3.2.1] octane containing compounds and their use in treatment of bacterial infections
WO2017206948A1 (zh) * 2016-06-03 2017-12-07 南京明德新药研发股份有限公司 新型二氮杂二环β-内酰胺酶抑制剂
SG11201810725WA (en) 2016-06-03 2018-12-28 Medshine Discovery Inc Novel β-lactamase inhibitors
WO2017216763A1 (en) * 2016-06-17 2017-12-21 Wockhardt Limited N-phenylalkoxy-7-oxo-6-sulfooxy-1,6-diazabicyclo[3.2.1]octane-2-carboxamide derivatives and their use as antibacterial agents
KR102537340B1 (ko) 2016-09-16 2023-05-26 엔타시스 테라퓨틱스 리미티드 베타-락타마제 억제제 화합물
JOP20190061A1 (ar) 2016-09-28 2019-03-26 Novartis Ag مثبطات بيتا-لاكتاماز
TW201831482A (zh) * 2017-02-06 2018-09-01 法商木塔比利斯公司 新穎雜環化合物及其預防或治療細菌感染之用途
MX2019010112A (es) * 2017-03-02 2019-10-15 Wockhardt Ltd Compuestos antibacterianos.
US10500195B2 (en) * 2017-03-02 2019-12-10 Wockhardt Limited Antibacterial compounds
MA48743A (fr) 2017-05-08 2020-04-08 Entasis Therapeutics Inc Composés et méthodes de traitement d'infections bactériennes
CA3076959C (en) 2017-09-27 2025-02-11 Meiji Seika Pharma Co., Ltd. CRYSTALLINE FORMS OF DIAZABICYCLOOCTANE DERIVATIVES AND THEIR PRODUCTION PROCESS
WO2019064065A1 (en) * 2017-09-27 2019-04-04 F. Hoffmann-La Roche Ag PHARMACEUTICAL FORMS OF DIAZABICYCLOOCTANE DERIVATIVES AND METHOD FOR THE PRODUCTION THEREOF
KR102844744B1 (ko) 2017-09-27 2025-08-11 메이지 세이카 파루마 가부시키가이샤 디아자비시클로옥탄 유도체의 약제학적 형태 및 그의 제조방법
ES2928152T3 (es) * 2017-12-01 2022-11-15 Qilu Pharmaceutical Co Ltd Forma cristalina de un inhibidor de beta-lactamasa y método de preparación de la misma
US11905286B2 (en) 2018-08-09 2024-02-20 Antabio Sas Diazabicyclooctanones as inhibitors of serine beta-lactamases
CA3110111A1 (en) 2018-08-09 2020-02-13 Antabio Sas Diazabicyclooctanones as inhibitors of serine beta-lactamases
EP4045040B1 (en) 2019-10-18 2023-04-05 Wockhardt Limited Nitrogen containing bicyclic compounds
WO2021165927A1 (en) * 2020-02-21 2021-08-26 Wockhardt Bio Ag 2-cyanopyrroldines, -piperidines or -dazepines as hyperglycemic agents
WO2022047790A1 (en) * 2020-09-07 2022-03-10 Ningxia Academy Of Agriculture And Forestry Sciences Amidine substituted bicyclic compounds, their preparation, their use as antibacterial agents and beta-lactamase inhibitors

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3615473A1 (de) 1986-05-07 1987-11-12 Basf Ag Verfahren zur herstellung von o-substituierten hydroxylaminen
US5925659A (en) * 1996-05-07 1999-07-20 Merck & Co., Inc. Antibacterial agents
FR2803592A1 (fr) * 2000-01-06 2001-07-13 Aventis Cropscience Sa Nouveaux derives de l'acide 3-hydroxypicolinique, leur procede de preparation et compositions fongicides les contenant.
FR2812635B1 (fr) * 2000-08-01 2002-10-11 Aventis Pharma Sa Nouveaux composes heterocycliques, preparation et utilisation comme medicaments notamment comme anti- bacteriens
FR2835186B1 (fr) * 2002-01-28 2006-10-20 Aventis Pharma Sa Nouveaux composes heterocycliques, actifs comme inhibiteurs de beta-lactamases
DE10256976A1 (de) * 2002-12-05 2004-06-24 Morphochem AG Aktiengesellschaft für kombinatorische Chemie Hydroxamsäuren als Methionin-Aminopeptidase (MAP) Inhibitoren
FR2848210B1 (fr) * 2002-12-06 2007-10-19 Aventis Pharma Sa Nouveaux composes heterocycliques, leur preparation et leur utilisation comme medicaments, notamment comme anti-bacteriens et inhibiteurs de beta-lactamases
CN101918407B (zh) * 2008-01-18 2014-02-26 默沙东公司 β-内酰胺酶抑制剂
FR2930553B1 (fr) * 2008-04-29 2010-05-21 Novexel Composes azabicycliques, leur preparation et leur utilisation comme medicaments, notamment inhibiteurs de beta-lactamases
WO2010024356A1 (ja) * 2008-08-27 2010-03-04 大正製薬株式会社 ナフチリジン－ｎ－オキシドを有する新規ヒドロキサム酸誘導体
FR2936798B1 (fr) * 2008-10-03 2012-09-28 Novexel Nouveaux composes heterocycliques azotes, leur preparation et leur utilisation comme medicaments antibacteriens.
US8796257B2 (en) 2011-12-02 2014-08-05 Naeja Pharmaceutical Inc. Bicyclic compounds and their use as antibacterial agents and β-lactamase inhibitors
WO2013180197A1 (ja) * 2012-05-30 2013-12-05 Ｍｅｉｊｉ Ｓｅｉｋａファルマ株式会社 新規β－ラクタマーゼ阻害剤とその製造法
WO2014033560A1 (en) * 2012-08-25 2014-03-06 Wockhardt Limited 1,6- diazabicyclo [3,2,1] octan- 7- one derivatives and their use in the treatment of bacterial infections

Also Published As

Publication number Publication date
ZA201500970B (en) 2016-10-26
JP2017128617A (ja) 2017-07-27
RU2614418C2 (ru) 2017-03-28
AU2015205914A1 (en) 2015-08-20
CN104768951A (zh) 2015-07-08
AU2013308127B2 (en) 2015-08-13
US9732081B2 (en) 2017-08-15
AU2015205914B2 (en) 2016-07-28
MX2015002177A (es) 2015-04-10
BR112015003592B1 (pt) 2020-04-14
AU2013308127A1 (en) 2014-07-10
US20180170930A1 (en) 2018-06-21
CA2881169A1 (en) 2014-03-06
EP2961751A1 (en) 2016-01-06
CN104768951B (zh) 2018-03-23
EP3360877B1 (en) 2021-02-17
US20150203503A1 (en) 2015-07-23
CA2881169C (en) 2020-06-16
JP6386132B2 (ja) 2018-09-05
EP2961751B1 (en) 2018-03-21
US20160213655A1 (en) 2016-07-28
US20200071328A1 (en) 2020-03-05
KR20150046066A (ko) 2015-04-29
ES2672100T3 (es) 2018-06-12
RU2015110500A (ru) 2016-10-10
EP3360877A1 (en) 2018-08-15
KR101946107B1 (ko) 2019-02-08
WO2014033560A1 (en) 2014-03-06
US10519155B2 (en) 2019-12-31
BR112015003592A2 (pt) 2017-07-04
JP2015526501A (ja) 2015-09-10
NZ626314A (en) 2017-02-24
US20160311822A1 (en) 2016-10-27
JP6329147B2 (ja) 2018-05-23

Similar Documents

Publication Publication Date Title
AU2015205914B2 (en) 1,6- diazabicyclo [3,2,1] octan- 7- one derivatives and their use in the treatment of bacterial infections
MX340533B (es) Derivados de 1,6- diazabiciclo [3,2,1] octan-7-ona y su uso en el tratamiento de infecciones bacterianas.
MX348974B (es) Derivados 1,6 - diazabiciclo [3,2,1] octan-7-ona y su uso en el tratamiento de infecciones bacterianas.
MX349827B (es) Compuestos que contienen nitrogeno y su uso.
AU2018256591A1 (en) Thieno[3,2-d]pyrimidines derivatives for the treatment of viral infections
MX2015007556A (es) Derivados de manosa para tratar infecciones bacterianas.
IN2012DN01269A (es)
MX2016009251A (es) Derivados de 7-oxo-1, 6-diazabiciclo [3.2.1] octano y su uso como agentes antibacterianos.
MX367897B (es) Derivados de piridazinona macrociclicos.
EA033311B1 (ru) Производные бензоксаборола в качестве антибактериальных средств
MX2016006432A (es) Tetrahidro-benzodiazepinonas.
NZ628294A (en) Compositions and methods of use of phorbol esters for the treatment of stroke
MX2014012477A (es) Inhibidores pirrolopirazona de tanquirasa.
PH12015501088A1 (en) Dimeric compounds
MX363678B (es) Terapia de combinación que comprende oxazolidinona-quinolonas para usarse en el tratamiento de infecciones bacterianas.
MX2015000362A (es) Benzo(b)-azepin-2-onas antiproliferativas.
HK1201836A1 (en) Novel pyrrole derivatives
PH12015500399A1 (en) Azaindolines
PH12015500185B1 (en) Azaheterocycles as bir2 and/or bir3 inhibitors
MX364443B (es) Agentes antimicrobianos.
WO2013166282A3 (en) Methods and compositions for treating bacterial infection
IN2013MU03216A (es)
MX2013009456A (es) Compuestos de azufre aromaticos sustituidos y metodos para su uso.
MX360040B (es) Nuevo agente antibacteriano derivado de florfenicol unido a sulfoximina y el uso del mismo en el tratamiento de infecciones bacterianas en ganado vacuno.
UA100955C2 (ru) Производные оксазина и их применение в лечении неврологических расстройств

Legal Events

Date Code Title Description
FG Grant or registration